tapinarof cream is a prescription medicine used To treat plaque psoriasis

Spesolimab, is a monoclonal antibody medication used for the treatment of generalized pustular psoriasis (GPP).

It is an interleukin-36 receptor (IL1RL2/IL1RAP) antibody. It was approved for medical use in the United States in September 2022.

Deucravacitinib, is a TYK2 inhibitor used for the treatment of moderate to severe plaque psoriasis. It was developed by Bristol Myers Squibb. It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).

Tildrakizumab, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Tildrakizumab is administered via subcutaneous injection. It is available as a single-dose prefilled syringe containing 100 mg of tildrakizumab in 1 ml of solution.

Vemurafenib (INN), is a medication used for the treatment of late-stage melanoma.

Talimogene laherparepvec is delivered by injecting it directly into tumors, thereby creating a systemic anti-tumor immune response.

Ipilimumab was approved by the U.S. Food and Drug Administration (FDA) in March 2011, to treat people with late-stage melanoma that has spread or cannot be removed by surgery.

Tirbanibulin is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

fluocinolone acetonide is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.